Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 894416 Versus Placebo in Healthy Male Japanese Subjects (Single-blind, Randomized, Placebo-controlled Within Dose Group)
Latest Information Update: 18 Aug 2023
Price :
$35 *
At a glance
- Drugs BI 894416 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI205424).
- 15 Feb 2021 Status changed from recruiting to discontinued.
- 22 Oct 2020 Status changed from not yet recruiting to recruiting.